Speakers

Marc Davies

Vice President of R&D • Leucid Bio

Marc Davies received his PhD from the laboratory of Dr John Maher at King’s College London, where his research focussed on the development and pre-clinical assessment of CAR T-cells targeting the extended ErbB family. This product is now under investigation in an investigator-led Phase I clinical trial for patients with relapsed/refractory head and neck cancer. Following a post-doctoral position at University College London developing CAR T-cells for haematological malignancies, Marc returned to KCL where his research focussed on enhancing CAR T-cell efficacy against solid tumours. With over 15 years of experience in the field of adoptive cell therapy, Marc joined Leucid Bio in May 2021 as VP of CAR Engineering to manage their burgeoning CAR T-cell R&D pipeline and clinical translation of their lead asset, LEU011.

Also speaking

Mantej Chhina

Executive Director, Head of Global R&D Regulatory Policy • BioMarin

George Eastwood

Board Chair, Interim Executive Director • Emily Whitehead Foundation

William Shingler

Head of Patient and Cell Management • Autolus Therapeutics

Event Info

Image

Advanced Therapies Investment Summit

Find out more about the Investor Pre-Day taking place 10th September 2024.
Image

2023 Sample Attendee List

Take a look at the sample attendee list for Advanced Therapies Europe 2023 here.